©The Author(s) 2025.
World J Gastroenterol. Dec 21, 2025; 31(47): 114651
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114651
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114651
Figure 1 Flow chart of study design and inclusion criteria.
NAFPD: Non-alcoholic fatty pancreas disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; MASH: Metabolic dysfunction-associated steatohepatitis; CT: Computed tomography.
- Citation: Heymann G, Rahman S, Kats D, Banini BA, Gaddam S, Aslanian E, Boateng S, Israel G, Muniraj T. Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2025; 31(47): 114651
- URL: https://www.wjgnet.com/1007-9327/full/v31/i47/114651.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i47.114651